Value of germline <i>BRCA</i> testing in patients with breast cancer: critical review of cost-effectiveness analyses using published value frameworks
No CEAs have assessed the value of early g<i>BRCA</i> testing or comprehensively modeled downstream impacts to RRS and PARPi use with consideration for broader value elements. Further studies are needed to assess the full value of early g<i>BRCA</i> testing strategies.
Authors
- Adam Kasle
- David L. Veenstra (ORCID: https://orcid.org/0000-0003-0687-0480)
- Yilin Chen (ORCID: https://orcid.org/0000-0003-0040-3881)
- Xiaoqing Xu (ORCID: https://orcid.org/0000-0001-8294-6307)
- Qixin Li (ORCID: https://orcid.org/0009-0006-9752-4696)
- Ashley Kang
- Amy Tung
- Lucille A. Sun
Institutions
- CURE International UK (GB)
- University of Washington (US)
- University of Veterinary Medicine in Košice (SK)
- AstraZeneca (Brazil) (BR)
- Corporación Universitaria Rafael Nuñez (CO)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-12-07
- DOI
- https://doi.org/10.1080/13696998.2025.2595887
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00